Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 13/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9893342 | 0.94 | TRPM8 (0.44) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9923988 | 0.91 | KDM4E (0.44) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9923971 | 0.90 | KDM4E (0.41) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9924011 | 0.89 | KDM4E (0.49) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9924012 | 0.88 | KDM4E (0.47) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9923989 | 0.86 | TRPM8 (0.44) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9924010 | 0.85 | TRPM8 (0.48) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9923982 | 0.85 | TRPM8 (0.45) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9924003 | 0.83 | KDM4E (0.41) | KDM4EMEN1LMNAPKMKMT2A | |
| SCHEMBL9924014 | 0.78 | TRPM8 (0.42) | TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-9067935-B2 | Imidazo[1,2-α]pyridine sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2015-06-30 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2012078994-A1 | IMIDAZO [1, 2-A] PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | WO | disclosed |
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, NV (BE) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149699-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | KDM4E 3480/4885MEN1 1061/4885LMNA 3025/4885 |
| US-20140088098-A1 | IMIDAZO[1,2-a]PYRIDINE SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPV1, TRPM2 | KDM4E 3480/4885MEN1 1061/4885LMNA 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.